BeiGene (BeOne Medicines Ltd.) announced that its compensation committee approved the issuance of 33,388 restricted share units (RSUs), equivalent to 434,044 ordinary shares, on 2 July 2026 under the Fifth Amended and Restated 2016 Share Option and Incentive Plan. The grant represents approximately 0.03% of the company’s total issued share capital.

The award covers 215 employees across the group. Each RSU corresponds to one American Depositary Share (ADS), with the ADSs closing at US$297.65—about HK$179.51 per ordinary share—on the grant date. No consideration is payable by the grantees.

Vesting terms stipulate that 25% of each grant vests on every anniversary of the last trading day of the month following an employee’s service-start date over four years, subject to continued employment. For two non-senior-management employees, the four-year vesting schedule starts on 30 June 2026. Certain termination or change-of-control events may accelerate vesting.

The RSUs carry no performance targets and are not subject to a clawback mechanism, a structure the board’s compensation committee deems consistent with market practice and the plan’s objectives of talent retention and motivation. Following this issuance, 113.72 million underlying shares remain available for future awards under the 2016 plan.

All grantees are employees; none is a director, chief executive, substantial shareholder, related entity participant, or service provider exceeding the individual limits set by Hong Kong’s Listing Rules.